ArticleCureus2025
Comparing Biologic Factor Composition of Birth Tissue-Derived Allografts and Platelet-Rich Plasma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Orthobiologic products are used for their regenerative potential, but variability in their composition may impact clinical outcomes. This study examined differences in key biologic factors among various products and preparation methods. Methodology Different formulations of platelet-rich plasma (PRP) and birth tissue-derived allografts were analyzed for specific biologic factors using laboratory assays. Results PRP demonstrated consistent biologic factor levels across samples, while allograft products exhibited notable variability. One category of birth tissue-derived products contained higher levels of a specific growth factor compared to others. Conclusions PRP showed greater consistency compared to allografts, which varied significantly between product lots. Standardization may improve the reliability of orthobiologic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.